CD33 and leukemia: Flow cytometry analysis revealed that mice treated with miR‐125b ASO‐loaded CD33‐targeting RBCEVs had much lower percentages of human leukaemia cells compared to control mice, indicating lower leukaemic burden and slower leukaemia progression (Figure 7F).